Allergan's acquired Tobira in November 2016: Al
Post# of 148309
Allerganwill acquire Tobira for an upfront payment of $28.35 per share, in cash, and up to $49.84per share in Contingent Value Rights (CVRs) that may be payable based on the successful completion of certain development, regulatory and commercial milestones, for a total potential consideration of up to $1.695 billion.